S4BA Share Price Performance
€0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
S4BA Community Narratives
There are no narratives available yet.
Recent S4BA News & Updates
F-star Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2022
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.04
- Gross Margin
- 100.00%
- Net Profit Margin
- -211.32%
- Debt/Equity Ratio
- 17.3%
F-star Therapeutics, Inc. Competitors
Snowflake Analysis
About S4BA
- Founded
- 2002
- Employees
- 86
- CEO
- WebsiteView website
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
U.K. Market Performance
- 7 Days: -0.4%
- 3 Months: 12.6%
- 1 Year: 12.8%
- Year to Date: 16.7%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 3.2%. As for the longer term, the market has risen 13% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›